CNJ.TO Cangene Cp
- 169 P/E
- 2.08 P/S
- 1.25 P/B
- -0.15 EPS
- 5.09% Cash ROIC
- 1.68 Cash Ratio
- 0 / 0% Dividend
- 255,197.00 Avg. Vol.
- 66.75M Shares
- 240.3M Market Cap.
Cangene Corporation develops, manufactures, and commercializes therapeutics for infectious diseases or biodefence applications in the United States, Canada, and internationally. The company develops hyperimmunes, which are concentrated specialty antibody preparations made from plasma; and recombinant biopharmaceuticals that are therapeutic proteins made by introducing a particular gene into a host...
MarketWatch - Feb 21, 2014
Canada NewsWire (press release) - Feb 21, 2014
Wall Street Journal - Feb 13, 2014
Wall Street Journal - Feb 18, 2014
Wall Street Journal - Mar 6, 2014
Washington Business Journal (blog) - Mar 7, 2014
Washington Business Journal - Mar 6, 2014
Seeking Alpha - Mar 7, 2014
StreetInsider.com (subscription) - Mar 5, 2014
Gazette.Net: Maryland Community News Online - Feb 28, 2014